Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Tiotropium bromide

Nature Reviews Drug Discovery volume 3, pages 643–644 (2004)Cite this article

Abstract

In January 2004, tiotropium bromide (Spiriva; Boehringer Ingelheim/Pfizer), an orally inhaled anticholinergic drug, was approved by the US FDA for the treatment of chronic obstructive pulmonary disease. Is it likely to become the bronchodilator of choice for this common and increasingly prevalent condition?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Anticholinergic drugs for the treatment of chronic obstructive pulmonary disease.
Figure 2: Market for drugs to treat COPD in US $ million.

References

  1. Barnes, P. J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 269–280 (2000).

    Article  CAS  Google Scholar 

  2. Lopez, A. D. & Murray, C. C. J. L. The global burden of disease, 1990–2020. Nature Med. 4, 1241–1243 (1998).

    Article  CAS  Google Scholar 

  3. Barnes, P. J. New treatments for COPD. Nature Rev. Drug Discov. 1, 437–446 (2002).

    Article  CAS  Google Scholar 

  4. Disse, B. et al. Ba 679 BR, a novel long-acting anti-cholinergic bronchodilator. Life Sci. 52, 537–544 (1993).

    Article  CAS  Google Scholar 

  5. Barnes, P. J. et al. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci. 56, 853–859 (1995).

    Article  CAS  Google Scholar 

  6. Casaburi, R. et al. A long-term evaluation of once-daily inhaled tiotropium bromide in chronic obstructive pulmonary disease. Eur. Respir. J. 19, 217–224 (2002).

    Article  CAS  Google Scholar 

  7. Vincken, W. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 19, 209–216 (2002).

    Article  CAS  Google Scholar 

  8. Donohue, J. F. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122, 47–55 (2002).

    Article  CAS  Google Scholar 

  9. Brusasco, V. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58, 399–404 (2003).

    Article  CAS  Google Scholar 

  10. FDA drug approvals list [online] (cited 10 June 2004) <http://www.fda.gov/cder/foi/label/2004/21395_spiriva_lbl.pdf> (2004).

Download references

Author information

Authors and Affiliations

  1. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Cynthia Mundy

  2. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Cynthia Mundy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia Mundy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mundy, C., Kirkpatrick, P. Tiotropium bromide. Nat Rev Drug Discov 3, 643–644 (2004). https://doi.org/10.1038/nrd1472

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1472

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing